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Abstract
Background: Colorectal cancer (CRC) diagnosis and the ensuing treatments can have a
substantial impact on the physical and psychological health of survivors. As the number of CRC
survivors increases, so too does the need to develop viable rehabilitation programs to help these
survivors return to good health as quickly as possible. Exercise has the potential to address many
of the adverse effects of CRC treatment; however, to date, the role of exercise in the rehabilitation
of cancer patients immediately after the completion of treatment has received limited research
attention. This paper presents the design of a randomised controlled trial which will evaluate the
feasibility and efficacy of a 12-week supervised aerobic exercise program (ImPACT Program) on
the physiological and psychological markers of rehabilitation, in addition to biomarkers of standard
haematological outcomes and the IGF axis.
Methods/Design: Forty CRC patients will be recruited through oncology clinics and randomised
to an exercise group or a usual care control group. Baseline assessment will take place within 4
weeks of the patient completing adjuvant chemotherapy treatment. The exercise program for
patients in the intervention group will commence a week after the baseline assessment. The
program consists of three supervised moderate-intensity aerobic exercise sessions per week for
12 weeks. All participants will have assessments at baseline (0 wks), mid-intervention (6 wks), post-
intervention (12 wks) and at a 6-week follow-up (18 wks). Outcome measures include cardio-
respiratory fitness, biomarkers associated with health and survival, and indices of fatigue and quality
of life. Process measures are participants' acceptability of, adherence to, and compliance with the
exercise program, in addition to the safety of the program.
Discussion: The results of this study will provide valuable insight into the role of supervised
exercise in improving life after CRC. Additionally, process analyses will inform the feasibility of
implementing the program in a population of CRC patients immediately after completing
chemotherapy.
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Background
Although early detection of and treatment for colorectal
cancer (CRC) have improved, the burden of this disease
remains high. One million new cases of CRC were diag-
nosed worldwide in 2002, which was just under 10% of
the world's total cancer incidence. In developed countries,
where western lifestyles make the disease more common,
incidence of CRC is second only to lung cancer [1].
Due to the relatively good overall prognosis for CRC
patients, in 2002 approximately 351 000 people in devel-
oped countries were living with CRC within 5 years of
diagnosis [1]. The majority of these patients underwent
surgery and, depending on the characteristics of the
tumour, chemotherapy and/or radiation. Although chem-
otherapy and radiation can greatly improve survival, they
are toxic and often cause side effects that remain even after
treatment is completed [2,3]. For these reasons CRC, as
well as a number of other cancers, is increasingly becom-
ing viewed as a chronic illness requiring longer-term man-
agement [4].
Although rehabilitation from cancer treatment continues
until an individual recovers any major loss of function (a
length of time which differs for every survivor), Courneya
and Friedenreich [5] have suggested that the period from
treatment completion to 3 to 6 months post-treatment be
described as the 'rehabilitation' phase. As is the case for
cardiac rehabilitation, the goal of rehabilitation after can-
cer treatment is to restore the person to good health as
quickly as possible, which for cancer survivors means
addressing the acute side effects resulting from the inher-
ent toxicity of cancer treatment [5]. Common physiologi-
cal and psychological side effects that remain after
treatment include fatigue, reduced quality of life,
decreased cardio-respiratory fitness, weight change, sleep-
ing disorders, suppression of the immune system, and an
increased risk of cancer recurrence and other chronic dis-
eases [5,6]. These side effects can persist for months and
even years following treatment completion; however, as
the majority of the acute effects of treatment are concen-
trated within the first 3 to 6 months post-treatment, this is
the time period in which survivors have the greatest need
for rehabilitation [5]. Furthermore, many survivors report
unanticipated fear and 'emptiness' after completing treat-
ment, in part because they experience a relatively sharp
down-turn in active medical and social support and they
receive little, if any, information about what to expect fol-
lowing treatment completion [7].
Exercise has the potential to be an effective and feasible
component of cancer rehabilitation. The rationale for the
use of exercise programs in the rehabilitation of cancer
survivors is two-fold. First, considerable evidence has
accumulated over recent decades indicating that exercise
and physical activity reduce symptoms and improve well-
being among people with chronic diseases, such as diabe-
tes, hypertension, coronary heart disease, chronic obstruc-
tive pulmonary disease, obesity, arthritis, and
osteoporosis [8]. Given the successful use of exercise reha-
bilitation programs in addressing the symptoms of
increased fatigue and reduced quality of life for cardiac
patients, it is reasonable to expect that exercise would
address these side effects in cancer patients. Second, there
is a growing body of evidence, primarily from the breast
cancer field, that suggests that exercise can play an impor-
tant role in cancer management across the cancer experi-
ence, from diagnosis to survival [5,6,9-14]. Results from
intervention studies suggest that exercise programs can
have positive impacts on fatigue [15,16], quality of life
[14], fitness [17], and immune function [18] among both
cancer patients and long-term survivors. Moreover, evi-
dence suggests that exercise is safe and feasible in cancer
survivor populations [19].
During the past 20 years numerous cross-sectional and
longitudinal have demonstrated that individuals who
exercise regularly have a lower risk of developing CRC
than sedentary individuals [11]. More recently, results
from prospective observational studies have shown a pro-
tective association between physical activity or exercise
after CRC diagnosis and survival [20,21].
Although evidence provides a strong rationale for the use
of exercise in the rehabilitation of CRC patients, the ques-
tion remains whether exercise interventions after CRC
treatment will yield similar benefits to those seen with
other chronic diseases and other cancer populations and
whether a protective association between physical activity
and CRC survival can be demonstrated through biologi-
cally plausible mechanisms monitored in an experimental
intervention trial.
One biologically plausible hypothesis to explain the
impact of exercise on CRC risk and prognosis is that exer-
cise may decrease insulin-like growth factor (IGF) bioa-
vailability via insulin-mediated changes in concentrations
of insulin-like growth factor binding proteins (IGFBP)
[22]. IGF-I plays a critical role in cellular proliferation and
survival [22], and elevated levels have been associated
with increased CRC risk [23]. In contrast, high pre-diag-
nosis levels of IGFBP-3 have been associated with pro-
longed survival after treatment [24]. If exercise programs
can modulate the IGF axis, the risk of new primary cancers
and cancer recurrence may be reduced. One study has pro-
vided evidence that exercise can impact biomarkers rele-
vant to the IGF axis: Fairey et al [25] reported significant
physiological changes in IGF-I, IGFBP-3 and IGF-I:IGFBP-
3 molar ratio after 15 weeks of moderate-intensity exercise
training in breast cancer survivors who were, on average,
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14 months post-treatment. The clinical significance of
these results and whether they can be replicated in CRC
survivors is unknown. It is possible that similar changes
could be evoked in a CRC population, and on the basis of
the results of the observational studies, these changes
could improve long-term prognosis.
Overall, evidence from previous studies suggests a strong
rationale for offering exercise interventions in CRC survi-
vors after treatment. However, the effectiveness of exercise
on the 3- to 6-month rehabilitation of CRC survivors has
not been investigated. For the general post-treatment time
period (i.e. the broad period from treatment completion
onwards), exercise intervention studies have predomi-
nately included breast cancer survivors [25-38] or mixed
cancer populations [39-46]. Only one study of an exercise
program after treatment exclusively recruited CRC survi-
vors, but the intervention was not during the early 'reha-
bilitation' time period [47]. Although the intervention in
that study was only two weeks in duration and the partic-
ipants were heterogeneous in terms of the number of
weeks since they completed treatment (from 4 – 40 weeks
post-treatment), the exercise intervention was found to
have a positive impact on CRC survivors' psychological
and physiological health. To date only one previous study
has focused specifically on rehabilitation in the time
period immediately following treatment and that was
with a breast cancer population. Hutnick and colleagues
[27] offered a supervised exercise program commencing
within 2–9 weeks of completion of breast cancer treat-
ment and found that a moderate-intensity exercise pro-
gram improved fitness and immune function and was
both safe and feasible in a post-chemotherapy popula-
tion.
Given that no study has evaluated the benefits of an exer-
cise rehabilitation program for CRC survivors in the early
rehabilitation period, there is much to be gained from
evaluating the feasibility and efficacy of an exercise pro-
gram in this population. Of particular need is a well
designed, randomised controlled trial of CRC survivors.
In light of the limited evidence supporting a beneficial
role of exercise for CRC survivors immediately after treat-
ment, the aim of this study is to investigate the effect of a
supervised exercise program on the rehabilitation of CRC
survivors immediately after treatment. As a phase one
trial, the study will be tightly controlled for intervention
parameters, such as exercise type, frequency, intensity and
duration. Outcomes include changes in psychological and
physiological markers of rehabilitation, in addition to
biomarkers of standard haematological outcomes and the
IGF axis. The process evaluation will focus on feasibility,
recruitment, program safety, participant compliance with
the intensity and duration of the exercise prescribed, and
participant perceptions of the exercise program. The proc-
ess evaluation is expected to yield information on factors
that may increase or hamper the effectiveness of the pro-
gram, information that may be crucial to the diffusion of
the intervention if the program is found to be effective.
We hypothesize that the exercise program will be accepta-
ble and safe for CRC survivors, that they will attend 90%
of the exercise sessions and will comply with their exercise
prescription. Additionally, we hypothesise that partici-
pants in the intervention group will have greater improve-
ments in fitness, fatigue and quality of life and greater
positive changes in IGF-1 and IGFBP-3 concentrations
than those in a 'usual-care' control group. The results of
this study will provide valuable new information about
the role of exercise in improving CRC rehabilitation and
survivorship.
Methods/Design
Overall aims of the study
To examine the effects of the ImPACT Program (I'm Phys-
ically Active after Cancer Treatment), a supervised exercise
program commenced within 4 weeks of completing
chemotherapy treatment, on psychological and physio-
logical markers of rehabilitation in CRC survivors and to
evaluate the feasibility of implementing such a program.
Primary aims
Outcome Evaluation
1. To examine the effects of a supervised exercise program
commenced within 4 weeks of completing chemotherapy
treatment on cardio-respiratory fitness, biomarkers associ-
ated with health and survival, and indices of fatigue and
quality of life in CRC survivors.
Process Evaluations
2. To assess the acceptability of the ImPACT Program to
CRC survivors, their adherence to the exercise program,
and their compliance with the prescribed duration and
intensity during supervised exercise sessions.
3. To assess the safety of the exercise program by monitor-
ing adverse events and changes in participants' haemato-
logical markers.
Patient Recruitment
Forty patients who are due to complete adjuvant chemo-
therapy treatment for CRC within the duration of the
study recruitment period will be recruited from oncology
clinics in Brisbane, Queensland, Australia. Ethical
approval for this study has been obtained from the partic-
ipating hospitals as well as from The Medical Research
Ethics Committee of The University of Queensland.
The treating oncologist will identify patients who are
potentially eligible (patients undergoing adjuvant chemo-
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therapy for CRC). A member of the clinic staff will then
provide information about the program to these patients
and seek permission for the program coordinator (RS) to
make contact with the patients. The program coordinator
will contact consenting patients to provide information
about the study requirements and assess them for eligibil-
ity. Eligible patients who initially agree to join the pro-
gram will be given a description of the program and, if still
interested, required to give written informed consent prior
to baseline testing, which will occur within 4 weeks of
treatment completion.
Patients will be recruited and will start the program on a
'rolling' basis, with an estimated 5 patients recruited per
month for 9 months (based on the current rate of patient
completion at the recruiting clinic). Forty patients are
expected to have been recruited and to have completed
involvement in the study within a 12-month period. It is
expected that results will be reported within 12 months of
the completion of the study.
Patient inclusion criteria
a. Aged between 18 and 75 years, with confirmed CRC
(stage I-III).
b. Treated for CRC with surgery before then completing
adjuvant chemotherapy treatment within the 4 weeks
prior to enrolment in the study.
c. Non-smokers (not having smoked during the previous
12 months).
d. Able to read, write and understand English.
e. Willing and able to attend supervised exercise sessions
3 times a week for a period of 12 weeks, with an intention
of achieving a 90% attendance.
Patient exclusion criteria
a. Metastatic or incurable CRC.
b. Physical/psychiatric impairments that would seriously
impair physical mobility.
c. Known contraindications for exercise (as assessed by a
pre-screening questionnaire modified from the Sports
Medicine Australia Pre-Exercise Screening System 2005
[48]).
Study Design
This study is designed as a two-group randomised control-
led trial (see figure 1 for flow of participants). After base-
line testing, patients will be allocated to either an
intervention group that receives the exercise program (EX)
or a control group that receives 'usual-care' (CG). The
exercise program will last 12 weeks and will start within
one week of baseline testing. To reduce drop-out of CG
participants, they will be offered an exercise program after
completing the final study assessment. Outcome meas-
ures will be assessed at baseline, at the mid-intervention
time point of 6 weeks, in the week after the intervention
period and 6 weeks after the intervention is completed
(weeks 0, 6, 12 and 18).
Randomisation
To ensure that the study groups are balanced for poten-
tially confounding variables, a dynamic form of randomi-
sation called 'minimisation' [49,50] will be used to
allocate patients to either EX or CG. Confounding varia-
bles for which the groups will be balanced are: age (< 50
years of age or ≥ 50 years of age), sex, and self-report phys-
ical activity history ('never regularly physically active' or
'regularly physically active before and/or during treat-
ment'). Randomisation will be performed by a computer
program designed for this purpose [51]. Participants will
be randomised at the completion of the baseline testing.
Power calculation and sample size
Fatigue was chosen as the primary outcome for comput-
ing sample size. Data used in the computation are from an
intervention with breast cancer survivors, as very little
research has been conducted with CRC survivors. Cour-
neya et al [32] reported a clinically significant decrease of
9.3 (± 10.2) in fatigue scores (as measured by the FACT-
fatigue scale, the same tool to be used in this study),
between baseline and the completion of a 15-week inter-
vention, among participants enrolled in a supervised exer-
cise program. A sample of 14 participants per group will
allow us to detect a change of this magnitude (i.e. 14%
difference) in FACT scores pre- to post-intervention and
between groups post-intervention, with a power of 80%
and an alpha level of 0.05. Assuming a 30% drop out rate,
we will need to recruit 40 participants, 20 in each group,
to allow us to detect these differences in fatigue.
Intervention
Participants randomised to EX will complete an aerobic
exercise session on three days of the week for 12 weeks. All
sessions will be completed under the guidance and super-
vision of an exercise physiologist. These sessions will be
scheduled for a time and location that is mutually conven-
ient to the participant and exercise physiologist.
EX participants will commence the program with sessions
of 20 minutes in duration (plus 5-minute warm-up and 5-
minutes cool-down at a light intensity) and with the guid-
ance of the exercise physiologist, will increase by week 10
to a duration of 40 minutes (plus warm-up and cool-
down). Similarly, exercise sessions will commence at a
'moderate' intensity (approximating 40–50% of heart rate
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Flow of participants through studyigure 1
Flow of participants through study.
Case ascertained by treating oncologist and patient referred to study 
Confirmation of eligibility 
Eligible 
Agree to participate 
Randomisation 
Refuse to participate 
Patient shows initial interest in involvement in study 
Patient not 
interested in 
involvement 
Ineligible
Mid (6-week) intervention assessment 
Post (12-week) intervention assessment 
+ 6 weeks follow-up (18-week) assessment 
Exercise Program Usual-care control group 
W
k 0 
W
k 1-6 
W
k 7-12 
W
k 18 
Baseline Assessment 
Exercise Program Usual-care control group 
Timeline
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reserve or a Rating of Perceived Exertion [RPE] of 11–12)
and will increase to a 'high' intensity (approximating 70–
80% of heart rate reserve or a RPE of 15–16) as the partic-
ipant is able over the 12-week exercise program. Although
the exercise 'goal' (i.e. to complete sessions of 40 minutes
at 'high' intensity) is identical for all participants, the exer-
cise prescription for each session will be individually tai-
lored to each participant. Therefore, some participants
may reach their exercise 'goal' earlier than others. The
framework for progression of the prescribed exercise
intensity and duration will be based on ACSM's exercise
prescription guidelines for both general [52] and chronic
disease populations [53].
The exercise physiologist will reassess and progress each
EX participant's exercise prescription throughout sessions,
increasing the duration and intensity of the sessions as the
participant is willing and able. Both heart rate and RPE
will be used concurrently and as appropriate for each par-
ticipant. Exercise prescription is recognised as an 'art'
which involves the combination of objective and subjec-
tive indices [52]. The concurrent use of heart rate and per-
ceived exertion more accurately achieves targeted work
rates than either measure alone, and RPE alone has been
shown to be effective in achieving a training effect that
does not differ significantly from that of heart rate alone
[54].
Heart rate will be recorded throughout the session by a
heart rate monitor (Polar s610i, Polar Electro Oy, Fin-
land) at 5-second epochs, and the participant's self-
reported RPE will be recorded by the exercise physiologist
at 5-minute intervals.
Control Group
The CG will receive 'usual-care' during the course of the
study. Usual care after adjuvant chemotherapy for CRC
patients is generally a single follow-up visit with the treat-
ing oncologist 6 months after completion of treatment.
From baseline testing until the final assessment at the 18-
week follow-up, CG participants will be instructed to
maintain their current physical activity level. To reduce
attrition, CG participants will be offered the exercise pro-
gram after the 18-week follow-up assessment.
Outcome measures
The exercise program will last for 12 weeks, with all out-
comes assessed at baseline, mid-intervention, post-inter-
vention, and 6-week follow-up (0, 6, 12 and 18 weeks, see
table 1) unless otherwise stated. A summary of the tool to
be used for each outcome is described in table 2.
Cardio-respiratory fitness
Cardio-respiratory fitness will be indirectly assessed using
the Modified Bruce Treadmill protocol, which is a sub-
maximal incremental exercise test [52]. Treadmill proto-
cols are popular in clinical testing because walking is a
familiar activity and uses a large muscle mass [55]. The
Modified Bruce Protocol is similar to the widely used
Bruce protocol; however, the treadmill is initially hori-
zontal rather than uphill, with the slope increasing to a
5%, 10% and 12% gradient in the 2nd, 3rd and 4th stages
respectively. Additionally, the first three stages are con-
ducted at a constant speed of 2.7 km/hr and with only the
4th stage increasing in speed (to 4 km/hr) [52]. These
modifications in protocol are important for older and
deconditioned populations, as the modifications increase
the likelihood of participants reaching an optimal test
duration of 8–12 minutes [56] before volitional fatigue or
heart rate targets require test termination (test terminates
when heart rate = 85% of [220 – age]).
Clinical populations often do not meet the 'steady-state'
heart rate requirement of VO2 prediction from submaxi-
mal exercise testing [55]. For this reason, the results of the
treadmill test will be reported as heart rate at the end of
the second stage of the test, as well as the estimated oxy-
gen cost (ie metabolic equivalent [METs]) for the last stage
completed [57]. Additionally, to ensure that comprehen-
sive fitness data are available for all participants, the 6-
minute walk test [58] will be performed by each partici-
pant after attempting the Modified Bruce Protocol. Partic-
ipants will have a rest of 15 minutes between these tests,
during which time they will complete written compo-
nents of the assessment. The 6-minute walk test is a vali-
dated, simple and safe test, often used with chronic heart
failure and chronic obstructive pulmonary disease
patients to assess the effects of a rehabilitation program
[59].
Biomarkers of health
Within 3 days of each assessment, participants will attend
a convenient, accredited pathology laboratory where
blood will be drawn from an antecubital vein by qualified
staff. To minimise acute responses and diurnal fluctua-
tions, blood tests will occur at least 48 hours after exercise
and between 7:30–10:00 am (participants will be asked to
schedule all their tests for approximately the same time of
day). All blood tests will be preceded by an overnight (12
hour) fast.
IGF-1 and IGFBP-3 will be measured at each assessment
time point. All analyses will be performed by one pathol-
ogy laboratory. Blood samples will also be stored at -70°C
for further analyses at a later date, if funding allows.
Fatigue
Fatigue will be assessed by the 13-item Fatigue Scale
(FACT-FS) of the FACIT measurement system [60]. The
FACT-FS was developed specifically for the cancer popula-
BMC Cancer 2007, 7:154 http://www.biomedcentral.com/1471-2407/7/154
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Table 1: Outcome variables for effect evaluation
Variable No. of items Baseline mid-int post-int fw
Primary and Secondary outcomes
Fatigue (FACIT-fatigue) [60] 13 Q Q Q Q
QoL standard (SF-36) [62] 36 Q Q Q Q
physical functioning 10 Q Q Q Q
social functioning 2 Q Q Q Q
role limitations – physical 4 Q Q Q Q
role limitations – emotional 3 Q Q Q Q
general medical health 5 Q Q Q Q
bodily pain 2 Q Q Q Q
vitality 4 Q Q Q Q
mental health 5 Q Q Q Q
general medical perceptions 1 Q Q Q Q
QoL cancer specific (EORTC QLQ-C30) [63] 30 Q Q Q Q
physical 5 Q Q Q Q
role 2 Q Q Q Q
cognitive 2 Q Q Q Q
emotional 4 Q Q Q Q
social 2 Q Q Q Q
fatigue 3 Q Q Q Q
pain 2 Q Q Q Q
nausea and vomiting 2 Q Q Q Q
global health and QoL 2 Q Q Q Q
Physical Fitness
MET value for final stage completed and heart rate at 
completion of second stage (Modified Bruce Submaximal 
Treadmill Protocol)
N/A EP EP EP EP
Field Test (6-minute Walk Test) N/A EP EP EP EP
Haematological Markers
Full blood count N/A P P P P
Full iron studies N/A P P P P
IGF-1 N/A P P P P
IGFBP-3 N/A P P P P
Additional Measures
Time since diagnosis 1 Q + MR
Stage of disease 1 Q + MR
Socio-demographic variables 10 Q
Physical Activity Behaviour
Self-report recall (Active Australia + history question) 18 + 2 Q+T T (no history) T (no history) T (no history)
PA Logbook 24 LOG LOG LOG LOG
BMI 2 EP EP EP EP
WHR 2 EP EP EP EP
Q = written questionnaire, EP = Exercise Physiologist (RS), LOG = self-report logbook, T = telephone-delivered questionnaire, P = pathology lab, 
MR = Medical Records, QoL = Quality of Life, BMI = Body Mass Index, WHR = Waist Hip Ratio
tion and has been shown to be valid and reliable in the
general cancer population [60].
Quality of life
As in a similar study by Adamsen et al [61], two quality of
life (QoL) questionnaires, the SF-36 [62] and the EORTC
QLQ-C30 [63], will be used to comprehensively cover the
different aspects of physical and psychosocial well-being.
The two instruments assess QoL at slightly different time
periods, with the SF-36 including questions about the cur-
rent period (15 items), the last 4 weeks (20 items) and the
past year (1 item). The EORTC QLQ-C30 focusses on the
current period (5 items) and the past week (25 items).
The 36-item SF-36 is a frequently used measure of well-
being in the general population, and it has been shown to
be valid and reliable in cancer populations [64]. It con-
tains eight subscales measuring general health concepts
and one global health question. Five of the subscales
(physical functioning, role limitations – physical, role
limitations – emotional, social functioning, and bodily
BMC Cancer 2007, 7:154 http://www.biomedcentral.com/1471-2407/7/154
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pain) measure degree of dysfunction, and three (general
health perceptions, vitality, and mental health) measure
the full range from negative to positive health conditions.
The 30-item EORTC QLQ-C30 was developed specifically
to measure health-related quality of life in cancer patients
and includes assessment of symptoms and side effects. Six
functional subscales (physical, role, cognitive, emotional,
social functioning, and global QoL) and eight symptom
subscales (fatigue, nausea/vomiting, pain, dyspnoea,
insomnia, appetite loss, constipation, and diarrhoea)
comprise the EORTC QLQ-C30 questionnaire. The
EORTC QLQ-C30 has been shown to have good validity
and reliability properties [63,65].
Feasibility
Program Acceptability
Participant feedback about the ImPACT program will be
collected using a structured written evaluation form at the
post-intervention (12-week) assessment. EX participants
will be asked how enjoyable they found the ImPACT Pro-
gram (five-point scale: "extremely enjoyable"- "not at all
enjoyable") and how they felt about attending the ImPACT
Program (five-point scale: "I looked forward to it all the
time"- "I did not look forward to it at all"). In addition, EX
participants will be asked open-ended questions about
the most and least enjoyable aspects of the ImPACT Pro-
gram, any improvements they noticed in themselves since
commencing the program, why they missed sessions, their
opinion of the timing of the program with regard to treat-
ment, whether they would recommend it to other cancer
survivors, and whether they intend to continue exercising.
Finally, participants will be asked if they would have pre-
ferred that the ImPACT Program had been 1) a group-
based, 2) an exercise program to do on their own, 3) as
offered – they liked the program as it was, or 4) OTHER
(asked to specify). They will be given the opportunity to
write any other comments about their experiences in or
perceptions of the program.
Adherence and Compliance
Adherence to the ImPACT Program will be defined as EX
participants' attendance at the exercise sessions, whereas
compliance will be defined as how closely they follow
their individualised exercise prescription for duration and
intensity at each exercise session. Attendance will be mon-
itored by the supervising exercise physiologist. Compli-
ance with the prescribed program will be measured
subjectively using RPE and objectively by the downloada-
ble heart rate monitors. Every 5 minutes the supervising
Table 2: Outcome variables for process evaluation
Process evaluation outcome variables Before/during intervention Follow-up
Attendance by patients
Number of sessions attended by each patient EP record -
Reason for stopping during the intervention Questionnaire -
Adherence by patient
Exercise intensity RPE EP record -
HR monitor download -
Exercise duration: minutes EP record -
HR monitor download -
Safety
Self report adverse effects (injury etc) EP record -
Full blood count Blood test Blood test
Anaemia (full iron studies) Blood test Blood test
Opinion about the program (EX only)
Enjoyment of the program - Questionnaire
Feelings about attending sessions - Questionnaire
Reasons for missed sessions - Questionnaire
Timing of the program - Questionnaire
Benefits from the program - Questionnaire
Plans to continue exercising - Questionnaire
Favourite/least favourite aspects of the program - Questionnaire
Recommending the program to other patients - Questionnaire
Recommendations for improvements - Questionnaire
Other comments about the program - Questionnaire
EP = Exercise Physiologist (RS), EX = Exercise group, HR = Heart Rate, RPE = Rating of Perceived Exertion
BMC Cancer 2007, 7:154 http://www.biomedcentral.com/1471-2407/7/154
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exercise physiologist will ask participants to state their
RPE, which will be recorded on the supervisor's record
sheet.
Safety
An adverse event will be defined as any adverse change
from a participant's baseline condition, regardless of
whether it is considered related to exercise training [32].
In addition to participant self-report of adverse effects on
an ad hoc basis, haematological parameters will be
assessed at 0, 6, 12 and 18 weeks. Analysis of full blood
count and full iron studies will allow monitoring of par-
ticipants' general health and identification of any partici-
pants whose health would be compromised by continued
involvement. Results of the full iron studies will also be
used to ensure that participants are not anaemic, as anae-
mia could confound self-report fatigue scores [66]. These
analyses will also provide the opportunity to identify any
differences in haematological parameters between study
groups. The protocol for these analyses is the same as pre-
viously described for the biomarkers.
Additional Measures
Additional variables will be assessed to gain a better
understanding of the participants and to allow for a com-
parison between groups. Socio-demographic characteris-
tics (gender, age, marital status, living arrangements,
education level and occupation) will be measured by self-
report at baseline. Health-related variables (eg disease sta-
tus, time since diagnosis, type of treatment, time since
treatment and other chronic conditions) will be assessed
at baseline by self-report and, if consent is given, con-
firmed by a review of medical records. Descriptive charac-
teristics (weight, height, waist and hip circumference) will
be measured at each assessment and used to calculate
body mass index and waist-hip ratio.
Physical Activity
Although not a primary outcome, physical activity behav-
iour will be assessed at baseline, mid-intervention, post-
intervention and 6-week follow-up. These data will be
used to compare physical activity levels between the study
groups and identify potentially contaminating levels of
physical activity external to the intervention. A physical
activity logbook, detailing sedentary, light, moderate and
high intensity physical activity lasting at least 10 minutes
per bout during the previous week, will be completed by
all participants for the week after each of the four assess-
ments. Diaries and logbooks require intensive effort from
participants, but the data collected are comprehensive and
represent the only way to measure all forms of activity,
including transport, work, home and leisure-time activity
[67]. In case there is poor compliance with the diaries,
physical activity will also be measured with the validated
Active Australia questionnaire [68-70], administered by
telephone the week after each assessment.
Additionally, supplementary questions, developed by the
researchers based on physical activity categories described
by Hayes et al [71], will be asked to investigate partici-
pants' recall of their physical activity level both in the year
before their cancer diagnosis and during cancer treatment
("no physsical activity", "sporadic or limited physical activity",
"regular physical activity"). These supplementary questions
will be asked in the baseline questionnaire and then again
a week later during the administration of the Active Aus-
tralia survey, to evaluate the test-retest reliability of the
questions.
Data Analysis
Descriptive techniques will be used to characterise study
participants. Data collected for the impact evaluation will
be analysed according to intention-to-treat and per-proto-
col principles. Specifically, differences between EX and
CG in changes in the outcome variables between baseline
and the 6-, 12- and 18-week assessments will be analysed
using linear regression models. EX participants will be
included in the per-protocol analysis if they attend 90% of
the exercise sessions. Data collected for the process evalu-
ation will be analysed using both quantitative and quali-
tative techniques.
Discussion
As improvements in CRC detection and treatment con-
tinue to extend the lives of CRC patients, increased atten-
tion has been given to improving the lives of survivors.
Although exercise interventions have shown some prom-
ise in attenuating treatment side-effects in other cancer
populations, no study to-date has looked at the benefit of
a supervised exercise program in the rehabilitation of CRC
survivors immediately following the completion of adju-
vant treatment. The results of this study will provide valu-
able insight into the role that a supervised exercise
program could play in improving quality of life after CRC.
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